Immuno-oncology - 1 News by Ligand Pharmaceuticals

Immuno-oncology - 1 News by Ligand Pharmaceuticals

image description

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs

10-Jul-2024 - APEIRON Biologics AG announced that its shareholders have entered into a definitive agreement to sell their APEIRON shares to US-based Ligand Pharmaceuticals Incorporated for USD 100 million. APEIRON shareholders are also entitled to additional consideration based on future commercial and ...

immuno-oncology cancer therapy neuroblastoma

These products might interest you

Singulator™ 100 and 200 von S2 Genomics New

Singulator™ 100 and 200 von S2 Genomics by Dunn

Tissue dissociation - automatic, fast and precise

High yield with high viability from as little as 1 mg of solid tissue

tissue dissociation systems
View product
Show all immuno-oncology
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,208 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now